Home
Obi Profile
Fees
Services
News
Publications
Contact
You are here:
Title Details
Search
Login
CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS
No-Receipt date
2018-01243 - 10/04/2018
No-Filing date
20180400987 - 10/04/2018
No-Granting date
3095437 - 15/05/2018
No-EPO application date
13869984.8 - 14/10/2013
No-EPO granting date
2941251 - 07/03/2018
Gazette No-Publication date of application
-
Gazette No-Publication date of granted patent
5/2018 - 29/08/2018
Expiration date
15/10/2033
Kind of title
Validation of European Patent
Legal status
NOT VALID
Priorities
US201361749695 P07/01/2013/US
Active Substance of Supplementary Certificates
-
IPC Classification
Ipc Class
A61P 35/02
A61P 35/00
A61K 45/06
A61K 31/4725
A61K 31/4709
A61K 31/4184
A61K 31/337
Related Documents
Related Titles
Owners
Code
Firstname
Surname
Address
Town
ZIP
Country
877606
AROG PHARMACEUTICALS, INC.
5420 LBJ FREEWAY SUITE 410
DALLAS, TX 75240
UNITED STATES OF AMERICA (USA)
Inventors
Code
Firstname
Surname
2181489
JAIN, VINAY, K.
Representatives
Code
Firstname
Surname
Address
Town
Zip
2011
VALI-VASILIKI
SAKELLARIDI
ADRIANOY 70
ATHINA (ATTIKIS)
10556
Contact
Code
Firstname
Surname
Address
Town
Zip
Country
5848
VALI-VASILIKI
SAKELLARIDI
ADRIANOY 70
ATHINA (ATTIKIS)
10556
GREECE
Owners History
Title Instruments
Date
Operation
Descreption
5/15/2024 12:00:00 AM
Έκπτωση Κύριων Τίτλων (79602)
ΕΚΠΤΩΣΕΙΣ 04/2024 Αρ. Πρωτ. ΓΔ 1555 / 15.05.24
Payments history
10 renewals have been done
© OBI all rights reserved
designed & developed by PROFILE S.A.
Certified QMS :
EN ISO 9001:2015
and
ΕΝ ISO 14001:2015
The project "Internet technological information diffusion from industrial property titles" is co-financed 70% by the European Regional Development Found and 30% by the Hellenic public sector (Operational programme "Competitiveness", Measure 4.4).